Novo Nordisk 2030 Strategy Targets Multiple Blockbusters

Novo Nordisk (NVO) unveiled its 2030 strategy at a Capital Markets Day in London on Sept. 21, 2026, outlining ambitions to broaden its pipeline and launch multiple blockbusters while emphasizing these targets are strategic aims, not formal financial guidance.

2030 Strategic Ambitions and Pipeline Goals

The company said in a press release that its 2030 ambition centers on three pillars: grow and diversify the pipeline, drive sustainable growth, and deliver attractive returns. Under the first pillar, Novo aims to launch more than five multi-blockbuster drugs by 2030 and achieve pipeline sales exceeding 150 billion Danish kroner (about $23 billion) by 2035. This sales target reflects the portfolio-level revenue expected from products currently in development, not a forecast for a single drug.

Novo plans to have at least five Phase 3 programs in obesity and diabetes and another five in other therapeutic areas by 2030. The strategy includes scaling oral GLP-1 (glucagon-like peptide-1) therapy capacity to serve ten times more patients with obesity and reaching over 60 million patients globally by 2030. The company also aims to deliver a 2026–2030 revenue compound annual growth rate (CAGR) aligned with a peer group of large pharmaceutical companies, including Eli Lilly, AstraZeneca, Gilead, Johnson & Johnson, AbbVie, Novartis, Sanofi, Roche, GSK, Amgen, Merck & Co., Biogen, Pfizer, and Bristol Myers Squibb. Novo intends to maintain broadly stable operating margins and an attractive dividend per share.[2]

Pipeline Development and Regulatory Status

Ahead of the CMD, Novo circulated materials for the European Association for the Study of Diabetes meeting (Sept. 28–Oct. 2) highlighting ongoing development of semaglutide in oral and injectable forms. These materials included real-world data on tablet formulations and details on higher-dose injection variants that support the company’s cardiometabolic pipeline and its case for multiple future blockbusters.[7]

No new regulatory approvals or filings were announced in connection with the CMD. Existing semaglutide approvals across injection and tablet formats—marketed as Wegovy, Ozempic, and Rybelsus—remain the commercial foundation for the company’s long-term ambitions.[7][10]

Near-Term Outlook and Market Concerns

In August 2026, Novo raised its 2025 sales and operating profit growth target at constant exchange rates to a range of flat to a 6% decline versus 2025, improving from a prior range of a 4% to 12% decline. This remains the most recent formal near-term outlook referenced around the CMD.[4]

Prior analysis shows semaglutide accounted for roughly 75% of Novo’s 2026 revenue, with models projecting it could represent about 59% of sales when key patents expire in Europe in 2031 and the U.S. in 2032. This concentration heightens the challenge of diversifying beyond Wegovy and Ozempic.[13]

Investor reaction to the CMD was cautious, with shares falling as some expressed disappointment over the lack of near-term clarity and flagged competition from Eli Lilly. Concerns about sustaining growth beyond the current semaglutide franchise remain central to market assessments. Progress in the planned Phase 3 programs and forthcoming clinical and real-world data will be key indicators of whether Novo can translate its numeric ambitions into commercial success.[3][4][5]

“All ambitions are by 2030 from a 2026 baseline, they are inherently uncertain and do not constitute Novo’s financial outlook or guidance,” the company said in its press release.[2]